Login Register Cart 0
Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Complications and Efficacy of Sinopharm Vaccine among Liver and Kidney Transplantation

Author(s): Mohsen Aliakbarian, Rozita Khodashahi*, Mahin Ghorban Sabbagh, Kambiz Akhavan Rezayat, Mandana Khodashahi, Ebrahim Khaleghi, Maliheh Dadgar Moghaddam, Baran Razmkhah, Mahdi Nik Nazar and Nadia Sheikhi

Volume 18, Issue 1, 2023

Published on: 13 May, 2022

Page: [15 - 22] Pages: 8

DOI: 10.2174/1574886317666220304122420

Price: $65

conference banner
Abstract

Background: There are various vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, vaccination may lead to some complications.

Objective: This study aimed to investigate the complications of transplant recipients who received the Sinopharm COVID-19 vaccine.

Methods: This was a retrospective cross-sectional study conducted among 667 transplant recipients (211 liver transplant recipients and 456 kidney transplant recipients) who received the Sinopharm COVID-19 vaccine from March to August 2021 and had medical records in Montaserieh Hospital, affiliated to Mashhad University of Medical Sciences, Mashhad, Iran. The demographic and clinical information, as well as patient's symptoms after each dose of the vaccine, were recorded.

Results: Only 16.8% and 13.7% of the patients experienced some symptoms following the first and second doses of the Sinopharm vaccine, respectively. No significant difference was observed between patients younger than 50 years and those aged 50 years and over in terms of the complication rate of the Sinopharm vaccine (P>0.005). Vaccine failure was reported in 10% of the cases; however, the mortality rate due to infection with the Delta variant of COVID-19 in this population was reported to be 0.7%.

Conclusion: Based on the obtained results, adverse reactions of the Sinopharm COVID-19 vaccine are generally mild, predictable, and non-life-threatening both in the first and second doses. Vaccine failure was reported in 10% of the cases; however, mortality due to infection with the Delta variant of COVID-19 was reported in less than 1% of the cases.

Keywords: COVID-19, side effects, transplant, vaccination, infection, sinopharm vaccine.

« Previous Next »
Graphical Abstract

[1]
Schaffer DeRoo S, Pudalov NJ, Fu LY. Planning for a COVID-19 vaccination program. JAMA 2020; 323(24): 2458-9.
[http://dx.doi.org/10.1001/jama.2020.8711] [PMID: 32421155]
[2]
Rume T, Islam SMD. Environmental effects of COVID-19 pandemic and potential strategies of sustainability. Heliyon 2020; 6(9): e04965.
[http://dx.doi.org/10.1016/j.heliyon.2020.e04965] [PMID: 32964165]
[3]
Bagcchi S. The world’s largest COVID-19 vaccination cam-paign. Lancet Infect Dis 2021; 21(3): 323.
[http://dx.doi.org/10.1016/S1473-3099(21)00081-5] [PMID: 33639124]
[4]
Ong E, Wong MU, Huffman A, He Y. COVID-19 coronavirus vaccine design using reverse vaccinology and machine learn-ing. Front Immunol 2020; 11: 1581.
[http://dx.doi.org/10.3389/fimmu.2020.01581] [PMID: 32719684]
[5]
Kaplan RM, Milstein A. Influence of a COVID-19 vaccine’s effectiveness and safety profile on vaccination acceptance. Proc Natl Acad Sci USA 2021; 118(10): e2021726118.
[http://dx.doi.org/10.1073/pnas.2021726118] [PMID: 33619178]
[6]
Dodd RH, Pickles K, Nickel B, et al. Concerns and motiva-tions about COVID-19 vaccination. Lancet Infect Dis 2021; 21(2): 161-3.
[http://dx.doi.org/10.1016/S1473-3099(20)30926-9] [PMID: 33338440]
[7]
Riad A, Pokorná A, Attia S, Klugarová J. Koščík M, Klugar M. Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. J Clin Med 2021; 10(7): 1428.
[http://dx.doi.org/10.3390/jcm10071428] [PMID: 33916020]
[8]
Fix OK, Blumberg EA, Chang KM, et al. AASLD expert panel consensus statement: Vaccines to prevent covid‐19 infection in patients with liver disease. Hepatology 2021.
[9]
Moosavi SA, Mashhadiagha A, Motazedian N, Hashemazar A, Hoveidaei AH, Bolignano D. COVID-19 clinical manifesta-tions and treatment strategies among solid-organ recipients: A systematic review of cases. Transpl Infect Dis 2020; 22(6): e13427.
[http://dx.doi.org/10.1111/tid.13427] [PMID: 32779820]
[10]
Nair V, Jandovitz N, Hirsch JS, et al. An Early Experience on the Effect of Solid Organ Transplant Status on Hospitalized COVID‐19 Patients. Am J Transplant 2020.
[PMID: 33443778]
[11]
Wang J, Jing R, Lai X, et al. Acceptance of COVID-19 Vac-cination during the COVID-19 Pandemic in China. Vaccines (Basel) 2020; 8(3): 482.
[http://dx.doi.org/10.3390/vaccines8030482] [PMID: 32867224]
[12]
Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and im-munogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021; 21(2): 181-92.
[http://dx.doi.org/10.1016/S1473-3099(20)30843-4] [PMID: 33217362]
[13]
Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vac-cine against SARS-CoV-2 on safety and immunogenicity out-comes: Interim analysis of 2 randomized clinical trials. JAMA 2020; 324(10): 951-60.
[http://dx.doi.org/10.1001/jama.2020.15543] [PMID: 32789505]
[14]
WHOW, World Health Organization (WHO): Evidence Assessment: Sinopharm/BBIBP COVID-19 vaccine frbtsagoesoipbtsw. 2021.
[15]
Sharma O, Sultan AA, Ding H, Triggle CR. A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Front Immunol 2020; 11: 585354.
[http://dx.doi.org/10.3389/fimmu.2020.585354] [PMID: 33163000]
[16]
Giannella M, Pierrotti LC, Helanterä I, Manuel O. SARS-CoV-2 vaccination in solid-organ transplant recipients: What the clinician needs to know. Transpl Int 2021; 34(10): 1776-88.
[http://dx.doi.org/10.1111/tri.14029] [PMID: 34450686]
[17]
Forni G, Mantovani A. COVID-19 vaccines: Where we stand and challenges ahead. Cell Death Differ 2021; 28(2): 626-39.
[http://dx.doi.org/10.1038/s41418-020-00720-9] [PMID: 33479399]
[18]
Jayadevan R, Shenoy RS, Anithadevi T. Survey of symptoms following COVID-19 vaccination in India. medRxiv 2021.
[http://dx.doi.org/10.1101/2021.02.08.21251366]
[19]
Hatmal MM, Al-Hatamleh MAI, Olaimat AN, et al. Side ef-fects and perceptions following covid-19 vaccination in Jor-dan: A randomized, cross-sectional study implementing ma-chine learning for predicting severity of side effects. Vaccines (Basel) 2021; 9(6): 556.
[http://dx.doi.org/10.3390/vaccines9060556] [PMID: 34073382]
[20]
Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med 2020; 383(27): 2603-15.
[http://dx.doi.org/10.1056/NEJMoa2034577] [PMID: 33301246]
[21]
Voysey M, Clemens SAC, Madhi SA, et al. Safety and effica-cy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised con-trolled trials in Brazil, South Africa, and the UK. Lancet 2021; 397(10269): 99-111.
[http://dx.doi.org/10.1016/S0140-6736(20)32661-1] [PMID: 33306989]
[22]
Doshi P. Covid-19 vaccine trial protocols released. British Medical Journal Publishing Group 2020.
[http://dx.doi.org/10.1136/bmj.m4058]
[23]
Lentine KL, Mannon RB, Josephson MA. Practicing with uncertainty: Kidney transplantation during the COVID-19 pandemic. Am J Kidney Dis 2021; 77(5): 777-85.
[http://dx.doi.org/10.1053/j.ajkd.2020.12.003] [PMID: 33388404]
[24]
Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm COVID-19 vaccination. Int J Infect Dis 2021; 111: 219-26.
[http://dx.doi.org/10.1016/j.ijid.2021.08.013] [PMID: 34384899]
[25]
FaHBF, Food and Health Bureau (FHB). Report on Evaluation of Safety EaQoCC-VVCIAohw 2021.
[26]
El-Shitany NA, Harakeh S, Badr-Eldin SM, et al. Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among Saudi residents: A retrospective cross-sectional study. Int J Gen Med 2021; 14: 1389-401.
[http://dx.doi.org/10.2147/IJGM.S310497] [PMID: 33907443]
[27]
Riad A, Abdulqader H, Morgado M, et al. Global prevalence and drivers of dental students’ COVID-19 vaccine hesitancy. Vaccines (Basel) 2021; 9(6): 566.
[http://dx.doi.org/10.3390/vaccines9060566] [PMID: 34072500]
[28]
Mazzola A, Todesco E, Drouin S, et al. Poor antibody re-sponse after two doses of SARS-CoV-2 vaccine in transplant recipients. Clin Infect Dis 2021; ciab580.
[http://dx.doi.org/10.1093/cid/ciab580] [PMID: 34166499]
[29]
Dumot JA, Barnes DS, Younossi Z, et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol 1999; 94(6): 1601-4.
[http://dx.doi.org/10.1111/j.1572-0241.1999.01150.x] [PMID: 10364031]
[30]
Carey W, Pimentel R, Westveer MK, Vogt D, Broughan T. Failure of hepatitis B immunization in liver transplant recipi-ents: Results of a prospective trial. Am J Gastroenterol 1990; 85(12): 1590-2.
[PMID: 2252022]
[31]
Kute VB, Agarwal SK, Prakash J, et al. NOTTO COVID-19 vaccine guidelines for transplant recipients. Indian J Nephrol 2021; 31(2): 89-91.
[http://dx.doi.org/10.4103/ijn.IJN_64_21] [PMID: 34267426]

Rights & Permissions Print Cite
Article Metrics
11
© 2024 Bentham Science Publishers | Privacy Policy